{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:29:56Z","timestamp":1787754596309,"version":"build-2784847793"},"reference-count":117,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.fjurol.2025.102952","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T21:34:23Z","timestamp":1763588063000},"page":"102952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)"],"prefix":"10.1016","volume":"35","author":[{"given":"Julien","family":"Anract","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Pinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Chevrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"Fassi-Fehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wilisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Gas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Rouscoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Della Negra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steeve","family":"Doizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhil","family":"Lebdai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9366","key":"10.1016\/j.fjurol.2025.102952_bib0005","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/S0140-6736(03)13073-5","article-title":"Benign prostatic hyperplasia","volume":"361","author":"Thorpe","year":"2003","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.fjurol.2025.102952_bib0010","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","article-title":"Bilan initial, suivi et traitement des troubles mictionnels en rapport avec hyperplasie b\u00e9nigne de prostate: recommandations du CTMH de l\u2019AFU","volume":"22","author":"Descazeaud","year":"2012","journal-title":"Prog Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2025.102952_bib0015","first-page":"1048","article-title":"[Conservative and pharmacological treatment of benign prostatic hyperplasia: The German S2e-guideline 2023-part2]","volume":"62","author":"Bschleipfer","year":"2023","journal-title":"Urol Heidelb Ger"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4111\/icu.2016.57.1.30","article-title":"Korean clinical practice guideline for benign prostatic hyperplasia","volume":"57","author":"Yeo","year":"2016","journal-title":"Investig Clin Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/JU.0000000000002183","article-title":"Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I-Initial Work-up and Medical Management","volume":"206","author":"Lerner","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0030","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","article-title":"EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction","volume":"64","author":"Oelke","year":"2013","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0035","doi-asserted-by":"crossref","first-page":"473","DOI":"10.11622\/smedj.2017082","article-title":"Singapore Urological Association Clinical Guidelines for Male Lower Urinary Tract Symptoms\/Benign Prostatic Hyperplasia","volume":"58","year":"2017","journal-title":"Singapore Med J"},{"key":"10.1016\/j.fjurol.2025.102952_bib0040","series-title":"The ADAPTE process: resource toolkit for guideline adaptation","year":"2009"},{"issue":"16","key":"10.1016\/j.fjurol.2025.102952_bib0045","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.purol.2012.10.001","article-title":"[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]","volume":"22","author":"Descazeaud","year":"2012","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0050","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline Amendment 2023","volume":"211","author":"Sandhu","year":"2024","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2025.102952_bib0055","first-page":"644","article-title":"[OCEBM levels of evidence system]","volume":"68","author":"Durieux","year":"2013","journal-title":"Rev Med Liege"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1464-410X.2009.08497.x","article-title":"The impact of self-management of lower urinary tract symptoms on frequency-volume chart measures","volume":"104","author":"Yap","year":"2009","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eururo.2004.02.008","article-title":"Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach","volume":"46","author":"Brown","year":"2004","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0070","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0090-4295(98)00475-0","article-title":"Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting","volume":"53","author":"Netto","year":"1999","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-5347(01)63011-8","article-title":"5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study","volume":"160","author":"Flanigan","year":"1998","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0080","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM199501123320202","article-title":"A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate","volume":"332","author":"Wasson","year":"1995","journal-title":"N Engl J Med"},{"issue":"7583","key":"10.1016\/j.fjurol.2025.102952_bib0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.39010.551319.AE","article-title":"Self management for men with lower urinary tract symptoms: randomised controlled trial","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1370\/afm.2609","article-title":"Self-management for men with lower urinary tract symptoms: a systematic review and meta-analysis","volume":"19","author":"Albarqouni","year":"2021","journal-title":"Ann Fam Med"},{"issue":"Suppl.\u00a02","key":"10.1016\/j.fjurol.2025.102952_bib0095","first-page":"S88","article-title":"Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate","volume":"147Suppl2","author":"Michel","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/nau.20481","article-title":"Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?","volume":"27","author":"Barendrecht","year":"2008","journal-title":"Neurourol Urodyn"},{"issue":"27","key":"10.1016\/j.fjurol.2025.102952_bib0105","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1097\/MD.0000000000000974","article-title":"Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis","volume":"94","author":"Yuan","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0110","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","article-title":"State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0115","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/jsm.12525","article-title":"Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis","volume":"11","author":"Gacci","year":"2014","journal-title":"J Sex Med"},{"issue":"25","key":"10.1016\/j.fjurol.2025.102952_bib0120","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0125","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2165\/00003495-200666030-00002","article-title":"Effects of alpha(1)-adrenoceptor antagonists on male sexual function","volume":"66","author":"van Dijk","year":"2006","journal-title":"Drugs"},{"issue":"4A Suppl","key":"10.1016\/j.fjurol.2025.102952_bib0130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0090-4295(98)00054-5","article-title":"Overview of alpha-blocker therapy for benign prostatic hyperplasia","volume":"51","author":"Narayan","year":"1998","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0140","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.juro.2007.09.084","article-title":"The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study","volume":"179","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2025.102952_bib0145","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","article-title":"A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia","volume":"62","author":"Nickel","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0150","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","article-title":"Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe","volume":"59","author":"Chapple","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.fjurol.2025.102952_bib0155","article-title":"The risk of fall and fracture with the initiation of a prostate-selective \u03b1 antagonist: a population based cohort study","volume":"351","author":"Welk","year":"2015","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.fjurol.2025.102952_bib0160","doi-asserted-by":"crossref","first-page":"e2343299","DOI":"10.1001\/jamanetworkopen.2023.43299","article-title":"Cardiovascular outcomes of \u03b1-blockers vs. 5-\u03b1 reductase inhibitors for benign prostatic hyperplasia","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0165","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JU.0000000000001561","article-title":"Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study","volume":"205","author":"Lusty","year":"2021","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0170","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/pds.4361","article-title":"Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia","volume":"27","author":"Duan","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.fjurol.2025.102952_bib0175","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/pds.5503","article-title":"Use of \u03b11-adrenoceptor antagonists tamsulosin and alfuzosin and the risk of Alzheimer's disease","volume":"31","author":"Latvala","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.fjurol.2025.102952_bib0180","doi-asserted-by":"crossref","first-page":"e2248135","DOI":"10.1001\/jamanetworkopen.2022.48135","article-title":"Association of 5\u03b1-reductase inhibitors with dementia, depression, and suicide","volume":"5","author":"Garcia-Argibay","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0185","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"31","author":"Chang","year":"2005","journal-title":"J Cataract Refract Surg"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0190","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ophtha.2010.08.039","article-title":"Risk factors for intraoperative floppy iris syndrome: a meta-analysis","volume":"118","author":"Chatziralli","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0195","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ophtha.2018.11.028","article-title":"Evolution in the risk of cataract surgical complications among patients exposed to tamsulosin: a population-based study","volume":"126","author":"Campbell","year":"2019","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0200","doi-asserted-by":"crossref","first-page":"252","DOI":"10.4081\/aiua.2022.2.252","article-title":"Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis","volume":"94","author":"Bapir","year":"2022","journal-title":"Arch Ital Urol Androl"},{"issue":"4 Pt 1","key":"10.1016\/j.fjurol.2025.102952_bib0205","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.juro.2006.06.004","article-title":"Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0210","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0090-4295(01)01448-0","article-title":"Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"issue":"4 Pt 1","key":"10.1016\/j.fjurol.2025.102952_bib0215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.ju.0000139539.94828.29","article-title":"Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0220","first-page":"814","article-title":"Evidence for atrophy and apoptosis in the prostates of men given finasteride","volume":"81","author":"Rittmaster","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0225","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0090-4295(99)00209-5","article-title":"Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study","volume":"54","author":"Bruskewitz","year":"1999","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0230","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0235","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0240","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0090-4295(02)01971-4","article-title":"Long-term (7- to 8-year) experience with finasteride in men with benign prostatic hyperplasia","volume":"60","author":"Vaughan","year":"2002","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","article-title":"Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial","volume":"61","author":"Kirby","year":"2003","journal-title":"Urology"},{"issue":"9","key":"10.1016\/j.fjurol.2025.102952_bib0250","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0255","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0090-4295(96)00353-6","article-title":"Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials","volume":"48","author":"Boyle","year":"1996","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0260","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0022-5347(05)64287-5","article-title":"Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss","volume":"168","author":"Donohue","year":"2002","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0265","first-page":"11473","article-title":"The impact of 5-ARI on perioperative and functional outcomes of GreenLight PVP: an analysis of the Global GreenLight Group database","volume":"30","author":"Elsherbini","year":"2023","journal-title":"Can J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0270","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.juro.2013.12.014","article-title":"Change in sexual function in men with lower urinary tract symptoms\/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy","volume":"191","author":"Fwu","year":"2014","journal-title":"J Urol"},{"issue":"13","key":"10.1016\/j.fjurol.2025.102952_bib0275","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.fjurol.2025.102952_bib0280","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jamaoncol.2022.1501","article-title":"Association of 5\u03b1-reductase inhibitors with prostate cancer mortality","volume":"8","author":"Bj\u00f6rnebo","year":"2022","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0285","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.juro.2012.09.099","article-title":"The REDUCE follow-up study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, follow-up study of men who participated in the REDUCE trial","volume":"189","author":"Grubb","year":"2013","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0290","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.juro.2016.11.082","article-title":"The cardiovascular safety of dutasteride","volume":"197","author":"Skeldon","year":"2017","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0295","doi-asserted-by":"crossref","first-page":"e0119694","DOI":"10.1371\/journal.pone.0119694","article-title":"Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study","volume":"10","author":"Hsieh","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.fjurol.2025.102952_bib0300","unstructured":"https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2013-01\/avodart_chibro_proscar_combodart_synthese_ct9291_9896_11612_12202.pdf."},{"issue":"25","key":"10.1016\/j.fjurol.2025.102952_bib0305","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0310","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000019706","article-title":"Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group","volume":"34","author":"Debruyne","year":"1998","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0315","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJM199608223350801","article-title":"The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group","volume":"335","author":"Lepor","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0320","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5489\/cuaj.520","article-title":"Finasteride monotherapy maintains stable lower urinary tract symptoms in men with benign prostatic hyperplasia following cessation of alpha blockers","volume":"2","author":"Nickel","year":"2008","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0325","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/pros.24663","article-title":"A prospective, randomized, open-label, parallel trial comparing the efficacy of \u03b1-blocker or 5\u03b1-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"84","author":"Lee","year":"2024","journal-title":"Prostate"},{"issue":"5 Pt 1","key":"10.1016\/j.fjurol.2025.102952_bib0330","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1097\/01.ju.0000140503.11467.8e","article-title":"Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action","volume":"172","author":"Buck","year":"2004","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0335","article-title":"Serenoa repens for benign prostatic hyperplasia","author":"Tacklind","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0340","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.pcan.4500746","article-title":"Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract","volume":"7","author":"Habib","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0345","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","article-title":"Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Novara","year":"2016","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0350","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0355","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1038\/s41598-017-15435-0","article-title":"Clinically meaningful improvements in LUTS\/BPH severity in men treated with silodosin plus hexanic extract of serenoa repens or silodosin alone","volume":"7","author":"Boeri","year":"2017","journal-title":"Sci Rep"},{"issue":"5\u20136","key":"10.1016\/j.fjurol.2025.102952_bib0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2680.2001.00231.x","article-title":"The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro","volume":"21","author":"Chess-Williams","year":"2001","journal-title":"J Auton Pharmacol"},{"issue":"17","key":"10.1016\/j.fjurol.2025.102952_bib0365","doi-asserted-by":"crossref","first-page":"9579","DOI":"10.1073\/pnas.97.17.9579","article-title":"Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype","volume":"97","author":"Matsui","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1 Suppl","key":"10.1016\/j.fjurol.2025.102952_bib0370","first-page":"S129","article-title":"Safety and tolerability of solifenacin add-on therapy to \u03b1-blocker treated men with residual urgency and frequency","volume":"189","author":"Kaplan","year":"2013","journal-title":"J Urol"},{"issue":"3 Pt 1","key":"10.1016\/j.fjurol.2025.102952_bib0375","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"issue":"19","key":"10.1016\/j.fjurol.2025.102952_bib0380","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0385","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/JU.0000000000003209","article-title":"Effect of pharmacotherapy for overactive bladder on the incidence of and factors related to urinary tract infection: a systematic review and meta-analysis","volume":"209","author":"Tsubouchi","year":"2023","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0390","doi-asserted-by":"crossref","first-page":"e0170726","DOI":"10.1371\/journal.pone.0170726","article-title":"Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS\u2122 for up to 1 year in adult men with both storage and voiding LUTS: a subanalysis of the NEPTUNE\/NEPTUNE II randomized controlled studies","volume":"12","author":"Drake","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0395","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1742-1241.2010.02611.x","article-title":"Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review","volume":"65","author":"Kaplan","year":"2011","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0400","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s41999-023-00798-7","article-title":"Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review","volume":"14","author":"\u0130lhan","year":"2023","journal-title":"Eur Geriatr Med"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0405","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","article-title":"Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0410","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2025.102952_bib0415","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/j.1464-410X.2011.10624.x","article-title":"Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving \u03b1-blocker treatment for lower urinary tract symptoms","volume":"109","author":"Kaplan","year":"2012","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0420","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/JU.0000000000003077","article-title":"Role of antimuscarinics combined with alpha-blockers in the management of urinary storage symptoms in patients with benign prostatic hyperplasia: an updated systematic review and meta-analysis","volume":"209","author":"Lenfant","year":"2023","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0425","doi-asserted-by":"crossref","first-page":"e0169248","DOI":"10.1371\/journal.pone.0169248","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. Bid HK, \u00e9diteur","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0430","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5213\/inj.1734850.425","article-title":"On the site and mechanism of action of \u03b23-adrenoceptor agonists in the bladder","volume":"21","author":"Andersson","year":"2017","journal-title":"Int Neurourol J"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0435","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the \u03b23-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102952_bib0440","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.urology.2018.03.038","article-title":"Mirabegron 25mg monotherapy is safe but less effective in male patients with overactive bladder and bladder outlet obstruction","volume":"117","author":"Liao","year":"2018","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0445","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/JU.0000000000003999","article-title":"Efficacy and safety of vibegron for persistent symptoms of overactive bladder in men being pharmacologically treated for benign prostatic hyperplasia: results from the phase 3 randomized controlled COURAGE trial","volume":"212","author":"Staskin","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.fjurol.2025.102952_bib0450","first-page":"2022","article-title":"Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis","volume":"11","author":"Kennelly","year":"2022","journal-title":"Drugs Context"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0455","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1111\/ijcp.12433","article-title":"Safety and tolerability of the \u03b23-adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised phase III trials and of a 1-year randomised phase III trial","volume":"68","author":"Nitti","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0460","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0465","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2025.102952_bib0470","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0475","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/nau.23935","article-title":"Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: a randomized, prospective trial using urodynamic studies","volume":"38","author":"Matsukawa","year":"2019","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0480","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/iju.14792","article-title":"Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: a randomized controlled trial","volume":"29","author":"Elbaz","year":"2022","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0485","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eururo.2012.09.006","article-title":"The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"63","author":"Giuliano","year":"2013","journal-title":"Eur Urol"},{"issue":"1S","key":"10.1016\/j.fjurol.2025.102952_bib0490","first-page":"S135","article-title":"Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial","volume":"189","author":"Dmochowski","year":"2013","journal-title":"J Urol [Internet]"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0495","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","article-title":"Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0500","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1743-6109.2011.02504.x","article-title":"Tadalafil 2.5 or 5mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study","volume":"9","author":"Egerdie","year":"2012","journal-title":"J Sex Med"},{"issue":"2","key":"10.1016\/j.fjurol.2025.102952_bib0505","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1757-5672.2011.00088.x","article-title":"Tadalafil administered once daily for treatment of lower urinary tract symptoms in korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control","volume":"3","author":"Kim","year":"2011","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0510","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.eururo.2011.08.005","article-title":"Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial","volume":"60","author":"Porst","year":"2011","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0515","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.juro.2008.06.079","article-title":"Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study","volume":"180","author":"Roehrborn","year":"2008","journal-title":"J Urol"},{"issue":"11","key":"10.1016\/j.fjurol.2025.102952_bib0520","article-title":"Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. Cochrane Urology Group, \u00e9diteur","volume":"2018","author":"Pattanaik","year":"2018","journal-title":"Cochrane Database Syst Rev [Internet]"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0525","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12144","article-title":"Tadalafil 5mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0530","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.juro.2014.11.094","article-title":"Time to onset of clinically meaningful improvement with tadalafil 5mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies","volume":"193","author":"Oelke","year":"2015","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0535","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with \u03b1-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0540","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.urology.2011.11.040","article-title":"Hemodynamic effects of once-daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant \u03b11-adrenergic antagonist therapy: results of a multicenter randomized, double-blind, placebo-controlled trial","volume":"79","author":"Goldfischer","year":"2012","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.fjurol.2025.102952_bib0545","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/bju.15027","article-title":"Tamsulosin and placebo vs. tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial","volume":"125","author":"Nagasubramanian","year":"2020","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.fjurol.2025.102952_bib0550","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.aju.2016.11.001","article-title":"Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"Fawzi","year":"2017","journal-title":"Arab J Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0555","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.jsxm.2017.06.006","article-title":"Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial","volume":"14","author":"Kim","year":"2017","journal-title":"J Sex Med"},{"issue":"8","key":"10.1016\/j.fjurol.2025.102952_bib0560","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00345-022-04071-7","article-title":"Prospective comparison of tadalafil 5mg alone, silodosin 8mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia","volume":"40","author":"AbdelRazek","year":"2022","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2025.102952_bib0565","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/0974-7796.120293","article-title":"Evaluation of the effect of sildenafil and\/or doxazosin on benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction","volume":"5","author":"Abolyosr","year":"2013","journal-title":"Urol Ann"},{"key":"10.1016\/j.fjurol.2025.102952_bib0570","doi-asserted-by":"crossref","first-page":"763184","DOI":"10.3389\/fphar.2022.763184","article-title":"Comparative efficacy of different drugs for lower urinary tract symptoms due to benign prostatic hyperplasia: a Bayesian network meta-analysis","volume":"13","author":"Fan","year":"2022","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.fjurol.2025.102952_bib0575","first-page":"CD010060","article-title":"Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia","volume":"11","author":"Pattanaik","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0580","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/UROS.UROS_59_19","article-title":"Combination alpha blocker and phosphodiesterase 5 inhibitor versus alpha-blocker monotherapy for lower urinary tract symptoms associated with benign prostate hyperplasia: a systematic review and meta-analysis","volume":"31","author":"Chen","year":"2020","journal-title":"Urol Sci"},{"issue":"3","key":"10.1016\/j.fjurol.2025.102952_bib0585","doi-asserted-by":"crossref","first-page":"102846","DOI":"10.1016\/j.fjurol.2024.102846","article-title":"Pre-therapeutical assessment of lower urinary tract symptoms in adult men: systematic review and clinical practice guidelines","volume":"35","author":"Lebdai","year":"2024","journal-title":"Fr J Urol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025000993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:03:37Z","timestamp":1767971017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025000993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":117,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950393025000993"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102952","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-interventional and medical management of lower urinary tract symptoms related to benign prostatic hyperplasia in men: Guidelines of the French LUTS Committee (CTMH)","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.102952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102952"}}